BMN 673
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BMN 673, covering 2017-05-24 to 2021-01-27. Get the full timeline:
Most recent: Clinical Trial Update: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations [Phase 1, Phase 2]